MintNeuro

MintNeuro operates at the intersection of semiconductor design, medical devices, neuroscience, and implantable brain-computer interfaces. Its differentiation is hardware-led: rather than presenting as a general neurotechnology platform, it develops purpose-built, modular integrated circuits for neural signal acquisition, stimulation, processing, power management, and wireless communication. The platform is intended to serve medical-device companies, researchers, and system integrators across preclinical and clinical development. The 2025 ARIA award of £17 million and the 2026 Motif Neurotech partnership indicate that MintNeuro is being used as an enabling component supplier within broader implantable-therapy programs. Its disclosed work also extends from epilepsy-focused neuromonitoring to mental-health applications and broader neuromodulation. Relative to software-first BCI companies, MintNeuro’s position is more specialized and infrastructure-oriented, centered on low-power, miniature, medical-grade silicon. Relative to conventional medical-device suppliers, its focus on customizable neural-interface electronics may provide greater integration flexibility, but commercialization, regulatory progress, clinical validation, and customer concentration remain important uncertainties.

MintNeuro’s trajectory shows a shift from early research funding toward larger-scale platform development and commercial integration. The company was founded in 2022 and received a £1.4 million grant on Jan 27, 2023, followed by £800,000 and £100,000 Innovate UK grants in May and July 2024. It then raised a disclosed £1 million seed round on Nov 12, 2024, led by Empirical Ventures alongside institutional and strategic participants. The major inflection point came on Jan 31, 2025, when ARIA awarded £17 million across three projects involving advanced chip technology for neural devices. That award materially exceeds the earlier disclosed financing and provides substantial support for engineering and translational work. Product scope now includes a modular neural-implant chip platform, a GOLD Project chipset, EXPLORE neural-sensing technology, and wireless intracranial neuromonitoring for drug-resistant epilepsy. The 2026 Motif Neurotech partnership adds a commercial pathway into miniature therapeutic implants for mental health and extends the company beyond standalone research programs. Public evidence supports expanding technical and partnership activity, but there is limited information on revenue, regulatory milestones, production scale, clinical outcomes, or employee growth beyond an estimated 11–50-person range.